Jaime Guevara-Aguirre, B.Sc., M.D.

//Jaime Guevara-Aguirre, B.Sc., M.D.

Jaime Guevara-Aguirre, B.Sc., M.D.

In 1987, Dr. Guevara-Aguirre founded the Institute of Endocrinology, Metabolism, and Reproduction (IEMYR) in Quito, Ecuador.  Since 1987, he has been the medical director of the IEMYR. In addition to his duties there, from 1990 to 1994 he was an instructor of endocrinology in the Department of Internal Medicine at the Central University in Quito.  In 1996, Dr. Guevara-Aguirre was scientific advisor to the vice president of Ecuador and a consultant to UNICEF. In 1997, he served as scientific advisor to the Minister of Health. Additionally, Dr. Guevara-Aguirre has served as a scientific advisor for Generex in Toronto, Canada, and Tercica in South San Francisco, California (now Ipsen Biopharmaceuticals, Inc., in Basking Ridge, NJ) and is currently a member of the scientific advisory board of Diagnostic Systems Laboratories, Inc., Webster, Texas.  From 2007 to the present, he has been professor in the Department of Pediatrics at the University of Florida College of Medicine.

Dr. Guevara-Aguirre earned a B.S. degree with majors in biology and chemistry from La Salle College and his M.D. degree in medicine and surgery at Central University both located in Quito, Ecuador.   He received extensive training in diabetes, general endocrinology, and reproductive biology at the National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Mexico.  He became a specialist in human reproductive biology (sub-specialty in hormonal peptide receptors) at the  National Autonomous University of Mexico.

Dr. Guevara-Aguirre is the recipient of the National Award for Research of the Ecuadorian Academy of Medicine in 1998, the Novartis Award for best Ecuadorian medical scientist in 1998, and the Vicente Rocafuerte Medal for Scientific Merit awarded by the National Congress of Ecuador in 2007.

He has published multiple peer-reviewed publications concerning gonadotropin membrane receptors, growth hormone receptor deficiency, alternative routes of insulin administration, and hormonal determinants of diabetes, cancer and dyslipidemias in humans with specific mutations.

2018-07-09T22:27:03+00:00